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With a €2 billion budget, the Innovative Medicines Initia-
tive (IMI) is the world’s largest public-private partnership
in health. Through its collaborative projects that bring
together experts from industry, academia, small and
medium-sized enterprises (SMEs), patient groups, and
regulators, IMI aims to develop tools and technologies
that will speed up the development of safer and better
drugs for patients and boost innovation in healthcare.
The European Union contributes €1 billion to the IMI
research programme through the Seventh Framework
Programme (FP7); this is matched by in kind contribu-
tions worth at least another €1 billion from the member
companies of the European Federation of Pharmaceutical
Industries and Associations (EFPIA).
IMI currently has 40 ongoing projects and more are in
the pipeline. The projects are delivering excellent results
that have an impact on all aspects of the drug develop-
ment procedure, from adding to our understanding of the
underlying biology of diseases, through the identification
of potential drugs and testing for safety and efficacy, to the
design of clinical trials.
Furthermore, through its projects, IMI is helping to
build a more collaborative ecosystem for pharmaceutical
research and development (R&D) in Europe. In this
environment, IMI projects are addressing obstacles to the
transfer of innovation into practice as well as involving
relevant groups such as regulators and patients. In
executing these collaborative projects, IMI acts as a neu-
tral trusted party, ensuring that intellectual property
rights are fairly distributed between partners.
Personalised medicine is a focus of many IMI projects.
Disease areas where IMI is working on patient stratifica-
tion and the tools needed to develop targeted, personalised
therapies include rheumatoid arthritis (RA) and related
immunoinflammatory conditions, diabetes, severe asthma,
and brain disorders such as autism, Alzheimer’s disease,
chronic pain, depression, and schizophrenia.
The projects’ approach to patient stratification and per-
sonalised medicine can take many forms, including the
development of patient reported outcomes, improving the
design of clinical trials based upon patient stratification, or
using electronic health records to speed up the identifica-
tion of better healthcare solutions. Furthermore, other IMI
projects contribute to this work, especially in the area of
knowledge management (as combining data from different
sources is not a simple task).
Looking to the future, the draft Strategic Research
Agenda of IMI 2 focuses explicitly on personalised
medicine – the working title is ‘The right prevention
and treatment for the right patient at the right time’.
Ultimately, it is hoped that IMI will provide socio-
economic benefits to European citizens, increase Europe’s
competitiveness globally and establish Europe as the
most attractive place for pharmaceutical research and
development.
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